News

Investigators coaxed human skin cells reprogrammed to act as stem cells to develop into layers of several types of retinal cells that sense light and ultimately transmit what we see to the brain.

To advance the company’s ability to anticipate on increasing patients’ needs and to pursue long-term growth plans in both fields of expertise, the company decided to spin out its retina division.

FT-001 is administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.

The investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.

Investigators concluded that both formulations of AR-1105 were well-tolerated and provided clinically meaningful and sustained visual improvements in vision and decreased retinal thickening despite that some patients had difficult-to-treat BRVO or CRVO with longstanding edema.

When dietary patterns were adjusted to include a Mediterranean diet, dietary nitrate intake was not associated with AMD progression independently.

The companies noted that the molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.

The investigators set out to determine how well ophthalmologists actually are represented when individuals conduct a Google search compared with their proportion in each U.S. county.

According to a research team from the National Eye Institute, part of the National Institutes of Health, the technique provides model for studying genesis of age-related macular degeneration and other eye diseases.

The use of heavy silicone oil tamponade in secondary surgery for persistent full-thickness macular holes is a safe and efficient surgical method. Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.

ROP is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.

As 2022 draws to a close, it has proven to be a year of interesting developments in retina, and the top headlines of the year bear this out.

In a news release, Opus said it will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.

The research team, led by Jayantha Gunaratne, PhD, senior principal investigator at IMCB, conducted a comprehensive analysis of the eye fluid samples from a well-defined cohort of proliferative DR patients against the control cohort to deduce impaired mechanistic aspects within the eye.

Korean biotech company MDimune Inc. and scientists from the Clear Vision Research Lab at The Australian National University hope to turn recent research milestones into potential treatments for AMD.

Derek Hodkey, president and CEO of Orbis International, discusses key achievements for the company and its Flying Eye Hospital in 2022 and offers his outlook for 2023.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

Steven J. Fliesler, PhD, has been named the 2022 recipient of the Retina Research Foundation’s (RRF) Paul Kayser International Award in Retina Research presented by the International Society for Eye Research (ISER).

The study, co-led by Griffith University’s Menzies Health Institute and South Korea’s Center for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technology, aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

The submission follows the U.S. FDA acceptance of the ONS-5010 BLA for wet AMD, with a PDUFA date of August 29, 2023.

According to University of Michigan investigators, the findings could help inform treatments for blindness in humans.

Lawmakers on Tuesday unveiled the $1.7 trillion proposed spending package needed to avert a government shutdown by Friday if both chambers can pass the measure this week.

Company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

Parexel teams with MyEyeDr. to leverage MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.

According to the company, RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Spanish investigators found that local resection may offer better visual results and eye sparing without compromising local tumor control and survival.

Investigators have found that cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.